Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine, propofol, and dexmedetomidine during electroconvulsive therapy for treatment-resistant major depressive disorder
IRCT20141209020258N143Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine, propofol and ketamine in major depressive disorder (MDD) (4 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Seizure duration, Patient satisfaction and 1 more. Started Jan 2020; status: completed.
02
Drugs
dexmedetomidinepropofolketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20141209020258N143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N143.